Ramosetron (n = 51) | Placebo (n = 52) | RR (95 % CI) | P value | |
---|---|---|---|---|
Atrial fibrillation | 11 (21.6 %) | 14 (26.9 %) | 0.80 (0.40 to 1.60) | 0.647 |
Atrial flutter | 1 (2.0 %) | 1 (1.9 %) | 1.02 (0.07 to 15.87) | 1.000 |
Ventricular tachycardia | 0 (0.0 %) | 0 (0.0 %) | ||
Ventricular fibrillation | 0 (0.0 %) | 0 (0.0 %) | ||
Bradycardia (heart rate <50 beats/min) | 0 (0.0 %) | 2 (3.8 %) | 0.495 | |
Tachycardia (heart rate > 100 beats/min) | 5 (9.8 %) | 8 (15.4 %) | 0.64 (0.22 to 1.82) | 0.555 |
Death from cardiac causes | 0 (0.0 %) | 0 (0.0 %) | ||
Myocardial infarction | 0 (0.0 %) | 0 (0.0 %) | ||
Unplanned coronary revascularisation | 0 (0.0 %) | 1 (1.9 %) | 1.000 | |
Stroke | 1 (2.0 %) | 1 (1.9 %) | 1.02 (0.07 to 15.87) | 1.000 |
Intensive care unit length of stay (day) | 2 (1 to 3) | 2 (1 to 4) | 0.912 | |
Hospital length of stay (day) | 9 (7 to 13) | 8.5 (7 to 13.75) | 0.350 |